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Abstract
Background: The calmodulin/calcium-activated K+ channel KCa3.1 is expressed in red and white blood cells, epithelia and
endothelia, and possibly central and peripheral neurons. However, our knowledge about its contribution to neurological
functions and behavior is incomplete. Here, we investigated whether genetic deficiency or pharmacological activation of
KCa3.1 change behavior and cerebral monoamine levels in mice.
Methodology/Principal Findings: In the open field test, KCa3.1-deficiency increased horizontal activity, as KCa3.12/2 mice
travelled longer distances (<145% of KCa3.1+/+) and at higher speed (<1.5-fold of KCa3.1+/+). Working memory in the Y-
maze was reduced by KCa3.1-deficiency. Motor coordination on the rotarod and neuromuscular functions were unchanged.
In KCa3.12/2 mice, HPLC analysis revealed that turn-over rates of serotonin were reduced in frontal cortex, striatum and
brain stem, while noradrenalin turn-over rates were increased in the frontal cortex. Dopamine turn-over rates were
unaltered. Plasma catecholamine and corticosterone levels were unaltered. Intraperitoneal injections of 10 mg/kg of the
KCa3.1/KCa2-activator SKA-31 reduced rearing and turning behavior in KCa3.1+/+ but not in KCa3.12/2 mice, while 30 mg/
kg SKA-31 caused strong sedation in 50% of the animals of either genotypes. KCa3.12/2 mice were hyperactive (<+60%) in
their home cage and SKA-31-administration reduced nocturnal physical activity in KCa3.1+/+ but not in KCa3.12/2 mice.
Conclusions/Significance: KCa3.1-deficiency causes locomotor hyperactivity and altered monoamine levels in selected
brain regions, suggesting a so far unknown functional link of KCa3.1 channels to behavior and monoaminergic
neurotransmission in mice. The tranquilizing effects of low-dose SKA-31 raise the possibility to use KCa3.1/KCa2 channels as
novel pharmacological targets for the treatment of neuropsychiatric hyperactivity disorders.
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Introduction
The calcium/calmodulin-activated K+ channel KCa3.1 [1,2] is
voltage-independent and its primary cell biological role is to
produce solid membrane hyperpolarization in response to
increases in intracellular calcium concentrations. KCa3.1 is widely
expressed in non-excitable tissues, e.g. erythrocytes (here known as
the Gardos channel) [3,4], white blood cells [5], salivary glands
[6], vascular endothelia [7,8] and intestinal and bronchial epithelia
[9]. In these tissues KCa3.1 channels contribute to cell volume
regulation, migration, and proliferation and thus play a role in
modulating immune responses, fibrosis, restenosis disease, blood
pressure, and fluid secretion [5,10]. Genetic deficiency of KCa3.1
in mice has been shown to produce splenomegaly (likely caused by
defective erythrocyte volume regulation) [3], endothelial dysfunc-
tion and mild systolic hypertension during locomotor activity
[8,11], but no overt immunological deficits. In the brain, KCa3.1
channels are expressed in the blood brain barrier (i.e. cerebrovas-
cular endothelium) [12] and in activated microglia [13,14] where
they are involved in respiratory burst [14], nitric oxide production
and inflammatory responses in the wake of ischemic stroke and
traumatic brain injury [15,16]. Whether or not KCa3.1 is also
expressed in central or peripheral neurons, is a matter of debate
since the initial cloning papers reported that KCa3.1 is absent
from neuronal tissue based on Northern blot analysis [1,17,18].
However, since then several studies reported expression of KCa3.1
in human dorsal root ganglia [19] and enteric neurons [20]. More
recently, KCa3.1 expression has also been reported in cerebellar
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Purkinje cells of the rat in which the channel has been shown to
contribute to after-hyperpolarizations and thereby regulation of
excitatory postsynaptic potentials by suppressing low frequencies
of parallel fiber input [21]. Despite these findings no behavioral
phenotype has been reported in KCa3.12/2 mice.
In contrast to KCa3.1, the three related KCa2.X channels
(KCa2.1, KCa2.2, and KCa2.3), which exhibit a smaller unitary
conductance but a similar calmodulin-dependent activation and
voltage-independence, are undoubtedly present in both the soma
and dendrites of central neurons [22,23]. While KCa2.1 and
KCa2.2 are most prominently expressed in the cortex and the
hippocampus, KCa2.3 is enriched in subcortical areas like the
striatum, thalamus and monoaminergic nuclei [24]. KCa2.X
channels shape neurotransmission and firing frequency by
underlying the apamin-sensitive medium after-hyperpolarization
(AHP) current and have accordingly been implicated in the
regulation of neuronal excitability, synaptic plasticity, learning,
and memory [25,26]. For example, mice in which KCa2.3-
expression can be suppressed by insertion of a tetracycline-
sensitive genetic switch exhibited working/short-term memory
deficits when treated with doxycycline (DOX) and an antidepres-
sant-like phenotype in the forced swim test [27,28]. These changes
were paralleled by enhanced dopamine and serotonin (5-HT)
signaling. Similarly, mice over-expressing KCa2.2 exhibit im-
paired hippocampal-dependent learning and memory in both the
Morris water maze and a contextual fear-conditioning paradigm,
while administration of the KCa2 channel blocker apamin
improves the performance of rats or mice in the water maze or
in the object recognition test (for recent complete review see [24]).
However, higher doses of apamin induce seizures [24].
While KCa2.X channels thus clearly play an important role in
the CNS, next to nothing is currently known about KCa3.1 in
CNS functions and behavior. One exception is the recently
reported observation that KCa3.12/2 mice are hyper-responsive
to restrain-induced stress as concluded from an enhanced
adrenocorticotropic hormone release from KCa3.1-deficient
Figure 1. Brain morphology and immunohistochemistry. (A) No overt differences between genotypes in morphology and amounts of glial
fibrillary acidic protein (GFAP)+ astrocytes and (B) of CD11b+ microglia in the molecular layer of the hippocampal CA1 region. (C) Immune
histochemistry of KCa3.1 in brain tissues from KCa3.1+/+ and KCa3.12/2 mice and (D) in human brain tissues, meningeal artery, and glioblastoma
multiforme together with a negative control (2AB).
doi:10.1371/journal.pone.0047744.g001
Table 1. Radiographic assessment of body composition of KCa3.12/2 and KCa3.1+/+ mice.
KCa3.1+/+ (n =6) KCa3.12/2 (n =7)
% difference of KCa3.12/2
relative to KCa3.1+/+ P-value
Total body mass, g 2561 2862 13 ,0.01
Bone Mineral Density, g/cmˆ2 0.04460.001 0.05260.002 16 ,0.001
Bone Mineral Content, g 0.3260.07 0.4260.02 29 ,0.05
Bone Area, cmˆ2 7.360.6 8.160.3 11 NS
% Fat tissue 2864 3162 11 NS
% Lean tissue 7264 6962 24 NS
doi:10.1371/journal.pone.0047744.t001
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corticotrophs of the pituitary and a subsequently higher cortico-
sterone level [29]. Our previous findings of systolic hypertension
primarily during locomotor activity [8] further raise the possibility
of altered sympathetic drive. In our present study, we therefore
hypothesized that the KCa3.1 channel might contribute to
behavioral regulation and that genetic KCa3.1 deficiency in mice
or pharmacological activation by systemic application of the
KCa3.1/KCa2.X activator naphtha [1,2–d] thiazol-2-ylamine
(SKA-31) [30] may cause behavioral alterations. Moreover, we
tested whether KCa3.1 deficiency and pharmacological activation
produce alterations in peripheral and/or central monoamine
levels. In addition, we sought to determine the impact of KCa3.1
deficiency on behavioral phenotypes caused by over-expression or
suppression of the related KCa2.3 channel.
Our behavioral studies demonstrate that genetic KCa3.1
deficiency enhances locomotor activity. These behavioral alter-
ations were paralleled by changes in central, but not peripheral
monoamine levels. In contrast, the KCa3.1/KCa2.X activator
SKA-31 produced hypoactivity and sedation in a dose-dependent
fashion.
Materials and Methods
Ethics Statement
Human tissue collection was performed by the Department of
Pathology, Odense University Hospital and approved by the
ethics committee of the University of Southern Denmark.
Informed consent for such stored and anonymized material
was not required and we obtained a waiver (CEIC No. 11/2012
and 13/2012) from our IRB to use this material. Animal
protocols were approved by the Danish authorities (Dyreforsøg-
stilsynet, No. 2009/561–1740).
Animals
Age- and sex-matched KCa3.12/2, KCa3.1+/+, KCa2.3T/T,
and KCa3.12/2/KCa2.3T/T mice [8,26,31] were derived from
our breeding colonies established at the Biomedical Laboratory,
University of Southern Denmark. In KCa3.12/2 mice, we
targeted the KCa3.1 gene by replacing exon-4 encoding for the
channel pore by a neomycin-resistance cassette. Loss of KCa3.1-
gene function was demonstrated by loss of KCa3.1-currents in
endothelial cells and T-lymphocytes [8]. The initial homozygous
mice were on a mixed 129S/SvEv x C57BL/6J background and
were then backcrossed over 8 generations onto a C57BL/6J
background. KCa3.1+/+ mice littermates were used as controls.
KCa3.12/2/KCa2.3T/T mice were derived from crossbreeding of
KCa2.3T/T mice (on a mixed 129S4/SvJae x C57BL/6J
background) onto the KCa3.12/2 background. KCa2.3T/T mice
(expressing wild type (WT) levels of KCa3.1) were derived from
the same breeding. In KCa2.3T/T mice, the insertion of a
tetracycline (T)-sensitive gene switch downstream of the endoge-
nous promoter results in a strong 10-fold over-expression while
dietary DOX treatment reduces gene expression by 90% leading
to an almost complete loss of functional KCa2.3 expression [26].
All animals used for this study were derived from inbred (strain)
breeding (3–4 generations) because of the double-transgenic
nature of the KCa3.12/2/KCa2.3T/T mice. Male C57BL/6J
mice were from Taconic Ltd (Ry, Denmark). Mice in all groups
were 361 month old. Subgroups of KCa2.3T/T and KCa3.12/2/
KCa2.3T/T mice received either 2 mg/ml DOX in 2% sucrose-
containing drinking water or only 2% sucrose-containing drinking
water for at least 2 weeks before experimentation. For SKA-31
injections, SKA-31 was dissolved in peanut oil and injected
intraperitoneally (i.p.) (injection volume: 100 ml) 30 min before
starting the open field test (OFT) or within the last 30–60 min of
the light phase.
Table 2. Radiographic assessment of body composition of KCa2.3T/T and KCa3.12/2/KCa2.3T/T mice.
KCa2.3T/T (n = 11)
KCa3.12/2/KCa2.3T/T
(n = 11)
% difference of KCa3.12/2/KCa2.3T/T
relative to KCa2.3T/T P-value
Total body mass, g 2661 3161 17 ,0.001
Bone Mineral Density, g/cmˆ2 0.05160.001 0.05360.001 2 NS
Bone Mineral Content, g 0.3660.02 0.4460.02 22 ,0.01
Bone Area, cmˆ2 7.060.2 8.360.3 19 ,0.01
% Fat tissue 2661 2861 9 P=0.09
% Lean tissue 7461 7261 23 NS
doi:10.1371/journal.pone.0047744.t002
Table 3. Radiographic assessment of hind limb composition of KCa3.12/2 and KCa3.1+/+ mice.
KCa3.1+/+ (n = 6) KCa3.12/2 (n = 7)
% difference of KCa3.12/2
relative to KCa3.1+/+ P-value
Hind limb mass, g 0.6060.04 0.6660.05 11 NS
Bone Mineral Density, g/cmˆ2 0.04360.001 0.05260.003 23 , 0.05
Bone Mineral Content, g 0.018160.0010 0.023460.0005 29 , 0.01
Bone Area, cmˆ2 0.4360.03 0.4560.02 6 NS
% Fat tissue 2765 3062 10 NS
% Lean tissue 7166 7063 22 NS
doi:10.1371/journal.pone.0047744.t003
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Behavioral tests
Open field test. OFT was performed with a non-transparent,
squared plastic box (45645645 cm) over a period of 10 min.
Movements were tracked using the SMART video tracking
software (Panlab, Barcelona, Spain) connected to a video camera
(SSC-DC378P, Biosite, Stockholm, Sweden). The distance trav-
elled (meter), speed (cm/sec), resting time, turns, and the entries
into the three zones (Wall, Inter peri and Center of the box) were
recorded automatically. Rearing, grooming, and droppings were
recorded manually and are given as number (n) of events [32].
Y-maze test. Spontaneous alteration behavior and hence
working memory was evaluated in KCa3.1+/+ and KCa3.12/2,
DOX-treated and untreated KCa2.3T/T and KCa3.12/2/
KCa2.3T/T mice using the Y-maze (arm length: 40 cm, arm
bottom width: 7 cm, arm upper width: 8 cm, height of the wall:
16 cm). Each mouse was placed in the arm designated (a) of the Y-
maze field. The number of entries, except for the first two, and
alterations were recorded manually. Data were collected for
8 min.
Grip strength test. The grip strength meter (BIO-GT-3,
BIOSEB, Sweden) was used to study the neuromuscular function
by determining the maximum force required for KCa2.3T/T,
KCa2.3T/T+DOX, KCa3.12/2/KCa2.3T/T and KCa3.12/2/
KCa2.3T/T+DOX mice to release their grips. Mice were allowed
to grasp the metal grid and then pulled backwards in the
horizontal plane. The force applied to the grip was recorded as the
peak tension. Total (both) front paw strengths were measured.
Each mouse was tested in 5 sequential trials and the highest grip
strength was recorded as the score [33].
The rotarod test. Was performed using a LE8200 system
(Panlab Harvard Apparatus). The full test consisted of two parts;
pre-training and 4 test trials (T1 – T4) [34,35]. Pre-training: mice
were pre-trained to stay and walk on the rod for 30 seconds at 4
rounds per minute (rpm). Mice that were not able to do this were
excluded from the subsequent test. All KCa3.12/2/KCa2.3T/T
and KCa3.12/2/KCa2.3T/T+DOX mice fulfilled the criteria for
the rotarod test, whereas 2 KCa2.3T/T and 2 KCa2.3T/T+DOX
mice were excluded from the test due to failure of fulfilling the
criteria in the pre-training. Trial: Prior to testing, the mice were
allowed to acclimatize in the behavior room for at least 1 hour.
Mice were placed on the rotarod and speed of the rotor was
accelerated from 4 to 40 rpm over 5 minutes. The latency to fall
from the rod was recorded automatically. Each mouse was tested
in 4 trials with 20 min resting time between each trial.
Tissue processing for histology
Mice were given an overdose of pentobarbital and perfused
through the left ventricle using 20 ml chilled 4% paraformalde-
hyde (PFA) in 0.15 M phosphate-buffered saline, pH 7.4 (Lam-
bertsen et al, 2009). Brains were quickly removed and post-fixated
in 4% PFA for 1 hour and either immersed in 20% sucrose
overnight, frozen and sectioned into a series of 8 parallel, 20 mm
thick cryostat sections, which were stored at 280uC until further
processing. Other brains were transferred to 1% PFA followed by
0.1% PFA, before serial cutting into 60 mm thick sections, which
were stored in de Olmos cryoprotective solution at 212uC until
further processing. One series of sections from each mouse was
stained with Toluidine blue for visualization of the general
histology [36].
Immunohistochemistry
Microglial CD11b and astroglial glial fibrillary acidic protein
(GFAP) were visualized in vibratome sections using a three-step
biotin-streptavidin-horseradish peroxidase (HRP) technique as
described in detail elsewhere [36]. KCa3.1 and KCa2.3 immu-
nohistochemistry (IHC) was performed on sections from paraffin-
embedded brain tissues. Sections were dewaxed with xylene,
rehydrated through an alcohol gradient, treated with 1.5% H2O2,
demasked with T-EG buffer, and incubated for 1 hour with
primary antibody in antibody diluent S2022. The following
primary antibodies (ABs) against KCa3.1 were used: Santa Cruz
sc-32949 (1:500), Alomone ALM-051 (1:2000), and Sigma
AV35098 (1:2000) followed by EnVision+polymer K4003(rab-
bit)/K4001(mouse). The ABs ALM-051 (1:2000) and Sigma
AV35098 gave similar results (not shown). Sections were visualized
with DAB and buffered Substrate Kit (Dako K3468), counter-
stained with hematoxylin and mounted with Aquatex. A second
set of staining with a different antigen retrieval protocol, a different
secondary antibody and the Vectastain kit was performed
independently and gave similar results [15]. For IHC studies on
KCa3.1 protein expression in human post mortem brain material,
paraffin-embedded tissue was kindly provided by the Department
of Pathology, Odense University Hospital and processed in the
same way. As negative control we processed sections omitting the
primary antibody (AV35098 against KCa3.1) or by substituting
the primary antibody with rat IgG2a isotype control (CD11b) or
rabbit serum (GFAP) as previously described [36].
High performance liquid chromatography analysis of
monoamines in plasma and brain samples and
corticosterone measurements
Mice were scarified by decapitation and blood (about 300 ml)
was collected in Eppendorf vials containing EDTA, centrifuged
(1,000 g for 10 min, 4uC) and the plasma (about 150 ml per
sample) was stored at220uC until further processing. Prior to high
Table 4. Radiographic assessment of hind limb composition of KCa2.3T/Tand KCa3.12/2/KCa2.3T/T mice.
KCa2.3T/T (n = 11) KCa3.12/2/KCa2.3T/T (n = 11)
% difference of KCa3.12/2/KCa2.3T/T
relative to KCa2.3T/T P-value
Hind limb mass, g 0.5560.04 0.6160.04 10 NS
Bone Mineral Density, g/cmˆ2 0.05460.003 0.05660.001 4 NS
Bone Mineral Content, g 0.01960.001 0.02260.001 15 P=0.07
Bone Area, cmˆ2 0.3560.01 0.3960.02 12 NS
% Fat tissue 2561 2661 7 NS
% Lean tissue 7463 7462 0 NS
Data in all tables are given as mean ± SEM and means were compared by unpaired Students T test.
doi:10.1371/journal.pone.0047744.t004
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Figure 2. Behavioral comparisons in the open field test. Rearing activity (A) was similar in KCa3.12/2 (2/2; n = 3) and KCa3.1+/+(+/+; n = 5) mice.
Increased rearing behavior was observed in untreated and DOX-treated KCa3.12/2/KCa2.3T/T (2/2/T/T2DOX, n = 5, and +DOX, n = 5) compared to
untreated and DOX-treated KCa2.3T/T (+/+/T/T (2DOX, n = 5, and +DOX, n = 7) mice. (B, C) Grooming behavior and droppings. (D) The mean total
distance travelled in the open field was significantly increased in KCa3.12/2 mice (n = 8) compared to KCa3.1+/+ mice (n = 10) and in untreated and
DOX-treated KCa3.12/2/KCa2.3T/T (2DOX, n = 6, and +DOX, n = 5) compared to untreated and DOX-treated KCa2.3T/T (2DOX, n = 5, and +DOX, n = 7)
mice. (E) Higher mean velocity in KCa3.12/2 and untreated and DOX-treated KCa3.12/2/KCa2.3T/T mice and representative SMART video tracking files.
(F) The number of entries into the different zones was similar in KCa3.12/2 and KCa3.1+/+, while untreated and DOX-treated KCa3.12/2/KCa2.3T/T mice
displayed a higher number of entries into the different zones compared to KCa2.3T/T mice. (G) Ratio between time spent at the margins and in the
center of the arena was significantly decreased in KCa3.12/2 mice compared to KCa3.1+/+ mice and tended to be increased in untreated and DOX-
treated KCa2.3T/T mice compared to KCa3.12/2/KCa2.3T/T mice. (H) Resting time was increased in untreated and DOX-treated KCa2.3T/T mice. (I)
Numbers of turns was similar in all genotypes and treatments. Data are given as means 6 SEM.* P,0.05, ** P,0.01, *** P,0.001, unpaired Student’s
T-test (KCa3.12/2 vs. KCa3.1+/+) and One-way ANOVA followed by Tukey’s Multiple Comparison test (KCa2.3T/T+/2DOX vs. KCa3.12/2/KCa2.3T/T+/
2DOX). Kruskal-Wallis followed by Dunn’s multiple Comparison test (in C).
doi:10.1371/journal.pone.0047744.g002
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performance liquid chromatography (HPLC) analysis, plasma
catecholamines were extracted using the ClinRepH complete kit
(Recipe GmbH, Munich, Germany).
After decapitation, the brain was quickly removed from the skull
and different brain regions were rapidly dissected, placed on dry
ice, weighed, and stored at 280uC. At the day of HPLC analysis,
the brain tissue samples were briefly sonicated in Eppendorf vials
containing 200–1000 ml (about 1:20 w/v) of 0.1 M perchloric acid
(PCA) with antioxidants (0.2 g/l Na2S2O5, 0.05 g/l Na2-EDTA)
and centrifuged at 20,627 g for 20 minutes at 4uC. The
supernatant was used for HPLC analysis.
Levels of noradrenalin (NA), dopamine (DA), serotonin (5-
hydroxytryptamine, 5-HT) as well as the DA metabolites 3,4-
dihydroxyphenylacetic acid (DOPAC) and homovannilic acid
(HVA), the NA metabolite 3-methoxy-4-hydroxyphenylglycol
(MHPG), and the 5-HT metabolite 5-hydroxyindoleacetic acid
(5-HIAA) were assessed by reverse-phase HPLC with electro-
chemical detection, essentially as described previously [37], but
using a mobile phase consisting of 10% methanol (v/v), 20 g/l
citric acid monohydrate, 100 mg/l octane-1-sulfonic acid sodium
salt, 40 mg/l EDTA dissolved in Milli-Q water and pH adjusted
to 4.0 [38]. The Merck-Hitachi HPLC system consisted of a L-
7100 pump a L-7200 autosampler, a D-7000 interface, and an
electrochemical detector with in-built column oven (Decade,
Antec, Leyden, Netherlands), connected to a computer equipped
with D-7000 version 2.0 chromatography software. The mobile
phase was pumped at a flow rate of 0.9 ml/min through a
Waters Spherisorb S5 ODS2 guard column (4.6630 mm) and a
Waters Spherisorb S3 ODS2 cartridge analytical column
(4.66150 mm, Waters, MA, USA). A mixture of external
standards was injected to identify and quantify the compounds
of interest.
Plasma corticosterone levels were determined in mice sacri-
ficed immediately after OFT and 40–45 minutes after treatment
with either vehicle or 30 mg/kg SKA-31. Corticosterone was
detected in 10 ml plasma samples (diluted 1:12) and quantified
using the DetectXHCorticosterone CLIA Kit (Arbor Assays, Ann
Arbor, Michigan) according to manufacturer’s instructions.
Telemetry
Telemetric recording of voluntary diurnal home cage activity
and analysis of data was performed after implanting a TA11-
PAC10 transducer (Data Sciences International (DSI), St Paul,
Minnesota, USA) as described previously [8].
Body composition measurements
Total tissue mass (g), fat mass (g), fat-%, lean tissue mass (g),
lean-%, bone area (cm2), bone mineral content (BMC, g), and
bone mineral density (BMD, g/cm2) were measured using dual-
energy X-ray absorptiometry (DXA) using a PIXImus2 (Version
1.44; Lunar Corporation, Madison, WI, USA).
Figure 3. Analysis of motor coordination, grip strength, and of working memory and explorative behavior. Rotarod: (A) Times
achieved on the accelerating rotarod in 4 consecutive trails (T1–T4); KCa2.3T/T (2DOX, n = 3, and +DOX, n = 5) and KCa3.12/2/KCa2.3T/T (2DOX, n= 6,
and +DOX, n = 5). Note that the KCa2.3T/T+DOX showed learning skills while this was not obvious in the other untreated or DOX-treated genotypes.
(B) Untreated or DOX-treated genotypes spend similar total times (sum of T1–T4) on the rotarod. (C) Grip strengths were similar in untreated and
DOX-treated genotypes; KCa2.3T/T (2DOX, n= 5, and +DOX, n = 6) and KCa3.12/2/KCa2.3T/T (2DOX, n = 6, and +DOX, n = 5). (D, E) Y-maze: KCa3.12/2
mice (n = 5) showed a similar number of entries (D) into the Y-maze but fewer alterations than KCa3.1+/+ mice (n = 8) (E). KCa2.3T/T2DOX (n= 6)
showed significant less entries into the arms of the Y-maze but a similar number of alterations compared to KCa3.12/2/KCa2.3T/TDOX (n= 7). The
DOX-treatment did not significantly change the number of entries and alterations of KCa3.12/2/KCa2.3T/T+DOX (n= 8) and of KCa2.3T/T+DOX (n= 5)
mice, although KCa2.3T/T+DOX showed by trend a higher number of entries and alterations than KCa2.3T/T mice. (D) * P,0.05, One-way ANOVA
followed by Tukey’s Multiple Comparison test. (E) * P,0.05, unpaired Student’s T-test.
doi:10.1371/journal.pone.0047744.g003
Behavioral Phenotypes in KCa3.1-Deficient Mice
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Statistics
Data are given as means 6 SEM. Data sets for corresponding
strains (KCa3.12/2 vs. KCa3.1+/+) and treatments (KCa3.12/2/
KCa2.3T/T vs. KCa2.3T/T; KCa3.12/2/KCa2.3T/T+DOX vs.
KCa2.3T/T+DOX, and untreated strains vs. DOX-treated strains)
were compared using unpaired or paired (SKA-31 treatments)
two-tailed Student’s T test if appropriate and as indicated in the
legend text. For testing differences in droppings we used the non-
parametric Kruskal-Wallis followed by Dunn’s multiple Compar-
ison test because of unequal variances in the groups. For multiple
comparisons of multiple data sets within one or of more than two
groups, we used One-way ANOVA followed by Tukey’s Multiple
Comparison test, if appropriate and as indicated in the figure
legends. Statistical analysis was performed using Prism 5 software
for Mac OS X, GraphPad Software. Statistical significance was
established for P,0.05.
Results
Body composition of KCa3.12/2, KCa3.1+/+, KCa2.3T/T, and
KCa3.12/2/KCa2.3T/T mice
Body weight was significantly higher in male KCa3.12/2 mice
(28.360.8 g, n= 20) than in male KCa3.1+/+ mice (23.560.7 g,
n = 17; P,0.001), but similar in female KCa3.12/2 mice
(20.460.4 g, n= 15) and female KCa3.1+/+ mice (19.460.7 g,
n = 19; P= 0.28). Also, male KCa3.12/2/KCa2.3T/T mice
(27.9 g60.6 g, n = 11) displayed a higher body weight compared
to male KCa2.3T/T mice (24.860.7 g, n= 11; P,0.01), while
body weights were again similar in female KCa3.12/2/KCa2.3T/
T mice (18.560.5 g, n= 10) and female KCa2.3T/T mice
(19.660.9 g, n = 9; P= 0.31). We found no morphological
alterations of major organs with the exception of mild spleno-
megaly in KCa3.12/2 mice and KCa3.12/2/KCa2.3T/T mice as
Figure 4. Impact of SKA-31 on locomotor activity in the open field environment and on spontaneous home cage activity in
KCa3.12/2 and KCa3.1+/+ mice. Effects of 10 mg/kg or 30 mg/kg SKA-31 (i.p.), or vehicle on distance travelled (A), mean velocity (B), grooming
behavior (C), droppings (D), rearing (E), number of turns (F), resting time (G), center/perimeter time ratios (H), and entries into the different zones (I).
In DOX-treated and untreated KCa2.3T/T and KCa3.12/2/KCa2.3T/T (right part of the graphs), 30 mg/kg, SKA-31 produced similar sedation.
Representative SMART video tracking files show lasting immobilization in one mouse of either genotype. Numbers in columns (A) are the numbers of
mice per group. Statistical comparisons were made between the different series of experiments (a–e) as indicated in (A) and by different column
fillings. *P,0.05; **P,0.01; unpaired Student’s T-test. (J) 24-hrs telemetric recording showed that KCa3.12/2 (n = 7) had higher diurnal home cage
locomotor activity (counts/min) than KCa3.1+/+ (n = 8). Note that the higher 24-hrs-average activity was due to a higher activity during the dark phase
(activity phase of mice). Data are given as means 6 SEM. * P,0.05; unpaired Student’s T-test. (K) SKA-31 (10 and 30 mg i.p at the end of the light
phase) lowered night locomotor activity in KCa3.1+/+ (10 mg, n= 5; 30 mg n= 3) but not KCa3.12/2 (10 mg, n = 5; 30 mg n=3). * P,0.05, before vs.
after SKA-31 injections in KCa3.1+/+; paired Student’s T-test.
doi:10.1371/journal.pone.0047744.g004
Figure 5. HPLC analysis of 5-HT (A) and its metabolite 5-HIAA (B), and turn-over rates (5-HIAA/5-HT) (C) in frontal cortex, striatum,
hypothalamus (only KCa3.12/2 and KCa3.1+/+), brain stem, and cerebellum. For vehicle (Ve) or SKA-31 experiments group sizes were n = 5
for KCa3.12/2 and KCa3.1+/+, for KCa2.3T/T2DOX n=5 and KCa2.3T/T+DOX n= 6, for KCa3.12/2/KCa2.3T/T2DOX n= 6, and for KCa3.12/2/KCa2.3T/
T+DOX, n= 5). * P,0.05, ** P,0.01; *** P,0.001, One-way ANOVA followed by Tukey’s Multiple Comparison test.
doi:10.1371/journal.pone.0047744.g005
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reported previously [8]. Our radiographic assessment of total body
mass, % lean mass, % fat mass, bone mineral density (BMD) and
bone mineral content (BMC) (Tables 1 and 2) as well as of the
same parameters in the hind limb (Tables 3 and 4) revealed no
major differences between genotypes, with the exception of higher
total body masses of male KCa3.12/2 mice (+3 g) compared to
male KCa3-1+/+ mice (Table 1) and of male KCa3.12/2/
KCa2.3T/T mice (+5 g) compared to male KCa2.3T/T mice
(Table 2) and a higher BMD and BMC in male KCa3.12/2 mice
compared to male KCa3.1+/+ mice (Table 1). General brain
morphology and structures of major brain regions showed no
abnormalities in any of the strains based on toluidine blue staining
(data not shown). Immunohistochemical staining for GFAP+
astrocytes and CD11b+ microglia revealed no apparent differences
in glial number or morphology in either genotype (Figure 1A and
B). Similar results were independently obtained when staining for
IBA+ microglia (data not shown). These results suggested that life-
long genetic deficiency of KCa3.1 or over-expression/suppression
(using DOX) of KCa2.3 do not result in gross alterations of brain
morphology. Specific immunoreactivity for KCa3.1 was not
detectable in neurons, astrocytes, or microglia from any brain
area of either genotype suggesting that KCa3.1 is not expressed at
immunohistochemically detectable levels in the normal murine
CNS (Figure 1C). Similar observations were previously made in
rat brain [15] and in our current study in human brain tissues, that
were found to lack KCa3.1-immunoreactivity (Figure 1D). In
contrast, positive KCa3.1 immunoreactivity was observed in
murine and human tissues such as endothelial cells (of human
meningeal artery in the present study) and glioblastoma multi-
forme (Figure 1D), which were previously shown to express
KCa3.1 [7,8,39,40].
Evaluation of behavioral phenotype in KCa3.12/2 mice
We investigated whether the lack of KCa3.1 could lead to
alterations in activity patterns, explorative behavior and/or
emotionality/fear in the open field environment (Figure 2). We
found that KCa3.12/2 and KCa3.1+/+ mice were similar in their
rearing and grooming behavior (Figures 2A and 2B). KCa3.1+/+
mice produced fecal pellets (droppings) while none of the
KCa3.12/2 did this in this test (Figure 2C). This difference did
however not reach statistical significance (P= 0.1). Interestingly,
KCa3.12/2 mice travelled a <1.5-fold longer distance than the
KCa3.1+/+ mice (P,0.01) (Figure 2D) and did this at a
significantly higher mean velocity in all zones (<1.4-fold,
P,0.01) (Figure 2E). Despite the increased mean velocity and
total distance travelled, the number of entries into the different
zones was similar in KCa3.12/2 and KCa3.1+/+ mice (P= 0.36)
(Figure 2F). The ratio of center time/perimeter time for the
KCa3.12/2 mice was significantly smaller (<50%) compared to
the ratio for KCa3.1+/+ mice (Figure 1G) (P,0.05). Resting times
(Figure 2H) as well as the numbers of turns were comparable
between the two genotypes (P = 0.36 and P= 0.78, respectively;
Figure 2I). To exclude that some of these significant differences
were simply caused by an abnormal low activity level in wild-type
littermate controls (KCa3.1+/+), we compared KCa3.1+/+ mice
(backcrossed onto C57BL/6J background over 8 generations) with
commercially available C57BL/6J mice and found that C57BL/6J
mice behaved similarly to KCa3.1+/+ mice in the open field
environment (Figure S1). Gender or body mass did not seem to
have an influence on these behavioral parameters studied since
KCa3.12/2 females with a body mass comparable to KCa3.1+/+
females behaved similar to KCa3.12/2 males with a higher body
mass compared to KCa3.1+/+ males (not shown).
In KCa2.3T/T or KCa3.12/2/KCa2.3T/T mice, over-expres-
sion of KCa2.3 or acute suppression of KCa2.3 by DOX
treatment did not change behavior in the open field environment
(Figure 2). However, KCa2.3T/T reared 5-times less than
KCa3.12/2/KCa2.3T/T (P,0.01) (Figure 2A), revealing sub-
stantial lower vertical explorative activity in these mice.
Grooming behavior was found to be similar (P = 0.18;
Figure 2B). However, the total number of droppings was
significantly increased in KCa2.3T/T compared to the
Figure 6. NA (A) and MHPG (B) levels in frontal cortex, striatum, hypothalamus (only KCa3.12/2 and KCa3.1+/+), brain stem, and
cerebellum. (C) NA turnover rates. Note that MHPG levels in the frontal cortex of KCa3.12/2/KCa2.3T/T were below the detection level in this analysis
(ND, not detected). For group sizes (n) see legend to figure 5. * P,0.05, ** P,0.01; *** P,0.001, One-way ANOVA followed by Tukey’s Multiple
Comparison test.
doi:10.1371/journal.pone.0047744.g006
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KCa3.12/2/KCa2.3T/T (P= 0.004; Figure 2C). The total
distance travelled in the open field box was shorter in the
KCa2.3T/T mice while KCa3.12/2/KCa2.3T/T mice covered a
3-fold longer distance (P,0.0001; Figure 2D). Similar to the
difference between KCa3.12/2 and KCa3.1+/+ mice, the high
horizontal activity in KCa3.12/2/KCa2.3T/T mice was paral-
leled by a 3-fold higher velocity in all zones compared to the low
velocity of KCa2.3T/T mice (Figure 2E) (P,0.001). Moreover,
KCa3.12/2/KCa2.3T/T mice showed an increased number of
entries into the wall, perimeter, and center zones compared to
KCa2.3T/T mice (P,0.05 and P,0.001; Figure 2F). Even
though there was a clear trend, the ratio of center time/
perimeter time for KCa3.2T/T mice was not statistically different
from that of KCa3.12/2/KCa2.3T/T mice (P = 0.064;
Figure 2G). Resting time was significantly higher in the
KCa2.3T/T mice than in the KCa3.12/2/KCa2.3T/T mice
(P,0.001; Figure 2H). The number of turns did not differ
between KCa2.3T/T and KCa3.12/2/KCa2.3T/T mice (P= 0.3;
Figure 2I). Taken together, the results from the open field
analysis of the different genotypes demonstrate that KCa3.1-
deficiency induces hyperactivity.
Analysis of motor coordination
KCa2.3 channels are expressed in dopaminergic neurons of the
substantia nigra [22,26] and the cerebellum [24,26,41] while
KCa3.1 channels have recently been reported to be present in rat
cerebellar neurons [21]. We therefore tested whether untreated or
DOX-treated KCa2.3T/T and KCa3.12/2/KCa2.3T/T mice
displayed alterations in motor coordination using the rotarod test
(Figure 3). The latencies to fall from the rotating rod in four
consecutive trials did not differ between groups and all four groups
spent similar total times on the rotarod, suggesting that expression
changes in KCa3.1 and KCa2.3 do not have any overt effect on
motor coordination (Figure 3A, B).
Figure 7. Levels of DA (A) and its metabolites DOPAC (B) in frontal cortex, striatum, hypothalamus (only KCa3.12/2 and KCa3.1+/+),
and brain stem in either genotype or treatment. For group sizes (n) see legend to figure 5. (C) Levels of the second DA metabolite HVA. Note
that HVA levels in the hypothalamus and brain stem were below the detection level in this analysis and DA turn-over rates are given as DOPAC/DA
ratios for these tissues. (D) DA-turnover rates. * P,0.05, ** P,0.01, One-way ANOVA followed by Tukey’s Multiple Comparison test.
doi:10.1371/journal.pone.0047744.g007
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Analysis of muscle force
We also studied whether the higher physical activity of
KCa3.12/2 mice was paralleled by increased muscle force, using
the grip strength test (Figure 3C). However, a major difference in
muscle force was not apparent, as grip strengths were comparable
in all groups. Nonetheless, there was a trend towards slightly
stronger grip strengths in untreated KCa2.3T/T mice compared to
untreated KCa3.12/2/KCa2.3T/T mice (P = 0.09). DOX treat-
ment did not alter muscle force in DOX-treated KCa2.3T/T mice
when compared to untreated KCa2.3T/T mice (P= 0.34). How-
ever, there was a trend for DOX treatment to reduce the grip
strength in KCa3.12/2/KCa2.3T/T mice (Figure 3C), even
though the difference did not reach statistical significance
(P = 0.09).
Analysis of working memory in KCa3.12/2 mice
To examine working memory, we performed the Y-maze test in
KCa3.1+/+, KCa3.12/2, KCa3.12/2/KCa2.3T/T and KCa2.3T/
T mice (Figure 3D and 3E). In this test, one can judge on working
memory by counting whether an animal remembers whether it
entered one arm of the Y-maze before and then explores the other
arm next (alteration). KCa3.12/2 and KCa3.1+/+ mice displayed
similar numbers of entries into each arm of the Y-maze
(Figure 3D). Alteration rate, however, was slightly decreased in
KCa3.12/2 mice compared to KCa3.1+/+ mice (P,0.05;
Figure 3E). When comparing KCa2.3T/T mice and
KCa3.12/2/KCa2.3T/T mice, the number of entries was strongly
decreased in KCa2.3T/T mice (P,0.01; Figure 3D). In fact, 3 of 6
KCa2.3T/T mice had less than 20 entries and alterations rate
ranged from 0% to 70%. However, after exclusion of the
KCa3.2T/T mice with less than 20 entries, alteration rates
appeared normal in the KCa3.2T/T mice (P = 0.81) while DOX-
treated KCa3.12/2/KCa3.2T/T mice showed a trend towards
decreased alteration rates compared to DOX-treated KCa3.2T/T
(P= 0.065; Figure 3E). These results suggested that working
memory was mildly impaired by KCa3.1-deficiency but not by
KCa2.3T/T over-expression or suppression. KCa2.3T/T mice
again displayed a decreased exploratory activity that could be
rescued by KCa3.1-deficiency. DOX-treatment did not influence
the performances of KCa3.2T/T and KCa3.12/2/KCa3.2T/T
mice (Figure 3D and E).
Behavioral impact of the KCa3.1-activator SKA-31 in the
open field environment and the effect of KCa3.1-
deficiency and SKA-31 on home cage locomotor activity
Since KCa3.1-deficiency produced hyperactivity, we hypothe-
sized that pharmacological activation of KCa3.1/KCa2.X chan-
nels by SKA-31 produces hypoactivity (Figure 4). At a dose of
10 mg/kg administered intraperitoneally 30 min prior to the open
field test, SKA-31 did not produce any overt differences in the
total distance travelled (Figure 4A) or the mean velocity (Figure 4B)
of KCa3.12/2 and KCa3.1+/+ mice. Grooming behavior and the
number of droppings were also unaffected (Figure 4C and 4D). In
contrast, SKA-31 produced low vertical explorative behavior
(rearing) in the KCa3.1+/+ mice but not in KCa3.12/2 mice
(P,0.001; Figure 4E). Moreover, SKA-31-treated KCa3.1+/+
mice made fewer turns than SKA-31-treated KCa3.12/2 mice
Figure 8. Plasma catecholamine and corticosterone levels. Levels of NA, adrenalin (ADR), and DA in plasma from KCa3.1+/+ and KCa3.12/2 (for
NA and ADR n= 12 per genotype; for DA: n= 7 (KCa3.1+/+) and n= 5 (KCa3.12/2) and in plasma from KCa2.3T/T(2DOX, n = 5, and +DOX, n = 5) and
KCa3.12/2/KCa2.3T/T (2DOX, n = 5, and +DOX, n = 5). Plasma corticosterone levels were unchanged in all genotypes and treatments. Ve: n = 4
(KCa3.1+/+) and n= 5 (KCa3.12/2; for SKA-31: n = 5 (KCa3.1+/+) and n= 5 (KCa3.12/2); KCa2.3T/T, n = 3 (2DOX), n = 2 (+DOX); KCa3.12/2/KCa2.3T/T, n = 5
(2DOX), n = 3 (+DOX).
doi:10.1371/journal.pone.0047744.g008
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(P,0.001; Figure 4F). Resting time, center/perimeter time ratios
and entries into the different zones were unchanged by the
treatment (Figure 4G–I). At the higher dose of 30 mg/kg, SKA-31
produced visible and lasting immobilization in 3 of 5 of the mice in
both genotypes (see representative tracings in Figure 4 and for all
tracings Figure S2), affecting all locomotor activity parameters
(Figure 4A–I), although if compared to vehicle-treated mice the
differences did not reach statistical significance because two mice
in each group did not respond to 30 mg/kg SKA-31 and produced
high variance within groups. In DOX-treated and untreated
KCa2.3T/T and KCa3.12/2/KCa2.3T/T, 30 mg/kg, SKA-31
sedated 2 or 3 mice of each group (n= 3–5, see Figure S2 for all
tracings) and e.g. rearing was nearly abolished (see right part of the
graphs in Figure 4A–I). After 90 minutes the sedated mice
recovered and freely travelled in the open field environment (see
tracings in Figure S2, bottom panel).
Because of the higher locomotor activity in the open field
environment, we were interested in further defining spontaneous
hyperactivity in KCa3.12/2 mice over longer time intervals.
Moreover, we wanted to know whether pharmacological channel
activation by SKA-31 in the presence of KCa3.1 had long-lasting
activity lowering effects. The 24-hours telemetric recording of
voluntary diurnal home cage activity (Figure 4J) revealed that the
average 24-hours-activity was higher in KCa3.12/2 mice than in
KCa3.1+/+ mice (<+47%, P,0.05). The increased activity level
was apparent during the normal activity phase, i.e. the dark phase,
(<+61%, P,0.05) but less obvious during the resting ‘‘light’’ phase
(<+20%, P= 0.15). Pharmacological activation of KCa3.1 in
KCa3.1+/+ gave the opposite results (Figure 4K). Injections of 10
and 30 mg/kg (i.p.) of SKA-31 into KCa3.1+/+ mice at the end of
the light phase decreased activity over 24 hours by <216%
(P,0.01) and <236% (P= 0.06), respectively, an effect being
most apparent during the dark phase (10 mg/kg: <222%,
P,0.01; 30 mg/kg: <249%, P,0.05). During the second
12 hrs period of the light phase the effect was smaller (10 mg/
kg: 25%, P= 0.14; 30 mg/kg: 28%, P= 0.17), which can be
explained by decreasing plasma levels due to metabolism of the
compound [30]. This activity lowering effect of SKA-31 was not
seen in KCa3.12/2 mice (Figure 4J–K).
These results suggested that SKA-31 produced low vertical and
home cage activity levels over at least 12 hours in a KCa3.1-
dependent manner, while the strong immobilization caused by the
high dose in some of the mice did not depend on KCa3.1 or
expression levels of KCa2.3 and is most likely due to the activation
of other KCa2 subtypes.
Central monoamine levels in KCa3.12/2, KCa2.3T/T, and
KCa3.12/2/KCa2.3T/T mice and after treatment with SKA-
31
HPLC analysis of several major brain areas revealed that
KCa3.1-deficiency did not alter 5-HT levels (Figure 5A) in the
frontal cortex, striatum, hypothalamus, cerebellum, and brain
stem of vehicle-treated KCa3.12/2 compared to vehicle-treated
KCa3.1+/+ mice. However, SKA-31 (30 mg/kg) significantly
increased 5-HT levels in the striatum and brain stem of
KCa3.1+/+ mice and also by trend in the striatum from
KCa3.12/2 mice. SKA-31 did not change 5-HT levels in frontal
cortex, hypothalamus, and cerebellum in either group.
In KCa2.3T/T+DOX mice, 5-HT-levels were increased in the
frontal cortex (+34%; P,0.01) while untreated KCa2.3T/T mice
showed a trend towards increased levels (+27%; P= 0.1) compared
to KCa3.12/2/KCa2.3T/T+DOX mice and untreated
KCa3.12/2/KCa2.3T/T mice, respectively. In the striatum, 5-
HT tended to be higher in KCa2.3T/T+DOX and untreated
KCa2.3T/T mice compared to KCa3.12/2/KCa2.3T/T+DOX
mice. In untreated KCa2.3T/T mice, brain stem levels of 5-HT
were higher than in KCa2.3T/T+DOX mice, untreated
KCa3.12/2/KCa2.3T/T mice, and KCa3.12/2/KCa2.3T/T+
DOX mice.
Levels of the 5-HT-metabolite, 5-hydroxyindoleacetic acid (5-
HIAA) (Figure 5B) were lower in the brain stem of KCa3.12/2
mice (P,0.01) and by trend in the hypothalamus (P= 0.11)
compared to KCa3.1+/+ mice. SKA-31 (30 mg/kg) further
reduced 5-HIAA levels in the brain stem of KCa3.12/2 but not
in KCa3.1+/+ mice. 5-HIAA was lower in the striatum (P,0.01) of
DOX-treated KCa3.12/2/KCa2.3T/T mice and by trend in
untreated KCa3.12/2/KCa2.3T/T+DOX mice (P= 0.1) com-
pared to DOX-treated KCa2.3T/T mice and untreated
KCa2.3T/T+DOX mice, respectively. 5-HIAA levels were not
significantly different in the other brain regions studied. Calculated
turn-over rates (5-HIAA/5-HT, Figure 5C) were significantly
reduced in the striatum (P,0.05), brain stem (P,0.05), and by
trend in the frontal cortex (P,0.1) of KCa3.12/2 mice compared
to KCa3.1+/+ mice and SKA-31 further decreased turn-over rates
in the frontal cortex of KCa3.12/2 mice (P,0.05) and in the
hypothalamus (P,0.05) and brain stem (P,0.01) of KCa3.12/2
and KCa3.1+/+ mice (Figure 5C). 5-HT turn-over rates (5-HIAA/
5-HT) were unchanged in KCa2.3T/T and KCa3.12/2/
KCa2.3T/T mice (see right part of the graphs in Figure 5C data).
In the analyzed forebrain areas, noradrenalin (NA) levels were
not changed by either genotype or treatment (Figure 6A).
However, vehicle-treated and SKA-31-treated KCa3.12/2 mice
showed significantly reduced NA levels in the brain stem
compared to vehicle-treated and SKA-31-treated KCa3.1+/+ mice
(P,0.01; Figure 6A). In addition, vehicle-treated KCa3.12/2
mice had lower NA levels in the cerebellum compared to vehicle-
treated KCa3.1+/+ mice. NA levels in the brain stem and
cerebellum of untreated or DOX-treated KCa3.12/2/KCa2.3T/T
and KCa2.3T/T mice were unaltered. Levels of the major NA
metabolite 3-methoxy-4-hydroxyphenylglycol (MHPG) (Figure 6B)
were not changed significantly by KCa3.12/2 deficiency or
treatments in any brain region. However, calculated NA turn-over
rate (MHPG/NA ratio) was higher in the frontal cortex of vehicle-
treated KCa3.12/2 mice (P,0.05) and by trend in SKA-31-
treated KCa3.12/2 mice (P= 0.1) compared to vehicle-treated
and SKA-31-treated KCa3.1+/+ mice, respectively. NA turn-over
rate was also higher in the brain stem of SKA-31-treated
KCa3.12/2 mice (P,0.05) and by trend of vehicle-treated
KCa3.12/2 mice (P= 0.1) compared to vehicle-treated and
SKA-31-treated KCa3.1+/+ mice, respectively. We did not find
significant changes in NA turn-over rates in untreated or DOX-
treated KCa3.12/2/KCa2.3T/T and KCa2.3T/T mice. But,
interestingly, MHPG levels were higher in the cerebellum of the
KCa2.3T/T and KCa3.12/2/KCa2.3T/T mice compared to
KCa3.12/2 and KCa3.1+/+ mice.
Dopamine (DA) levels were unaltered by genotype, the SKA-31
treatment, or the DOX treatment in the striatum, frontal cortex,
and brain stem, (Figure 7A), with the only exception of a higher
DA level in the hypothalamus of SKA-31-treated KCa3.12/2
mice compared to any of the other groups (P,0.05). Also levels of
the dopamine-metabolite 3,4-dihydroxyphenylacetic acid (DO-
PAC) were unaltered by genotype or treatments (Figure 7B). The
other DA metabolites homovannilic acid (HVA) was found at
detectable levels in the frontal cortex and striatum, but not in brain
stem or hypothalamus (Figure 7C). HVA levels were not
significantly changed in the frontal cortex and striatum of
KCa3.12/2 mice compared to KCa3.1+/+ mice (P= 0.46 and
P= 0.25, respectively). Also after the SKA-31 treatment, HVA
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levels were not significantly different in these mice. In contrast,
significantly lower levels of HVA were found in the frontal cortex
of untreated KCa3.12/2/KCa2.3T/T (P,0.05) and by trend in
the frontal cortex of DOX-treated KCa3.12/2/KCa2.3T/T DOX
(P=0.07) compared to untreated KCa2.3T/T and DOX-treated
KCa2.3T/T+DOX mice, respectively. HVA levels were signifi-
cantly lower in the striatum of DOX-treated and untreated
KCa3.12/2/KCa2.3T/T mice compared to the respective treated
or untreated KCa2.3T/T mice (P,0.05). Despite these differences,
DA turn-over rates (DOPAC+HVA/DA ratio) in the frontal
cortex and striatum were unaltered by genotype, the SKA-31
treatment, or the DOX treatment (Figure 7D). In contrast, the
DOPAC/DA ratio was significantly lower in the brain stem of
KCa3.12/2 mice compared to KCa3.1+/+ mice (P,0.05) and the
SKA-31 treatment reduced DOPAC/DA ratios in both genotypes
(P,0.01). DOPAC/DA ratios were similar in untreated or DOX-
treated KCa3.12/2/KCa2.3T/T and untreated or DOX-treated
KCa2.3T/T mice. In the hypothalamus, DOPAC/DA ratios were
similar in KCa3.12/2 and KCa3.1+/+ mice as well as after the
SKA-31 treatment in these mice.
GABA levels were not altered in KCa3.12/2 mice or by the
SKA-31 treatment (Figure S3).
Circulating catecholamine and corticosterone levels in
KCa3.12/2, KCa2.3T/T, and KCa3.12/2/KCa2.3T/T mice
Plasma catecholamine levels (NA, adrenalin (ADR), DA) were
assessed at the day of sacrifice and were found not to differ
between KCa3.12/2 and KCa3.1+/+ mice as well as between
KCa3.12/2/KCa2.3T/T and KCa2.3T/T mice with or without
DOX-treatment (Figure 8). However, it appeared that untreated
KCa2.3T/T mice had higher NA levels than KCa3.12/2
(P = 0.002) and KCa3.1+/+ mice (P= 0.012). Plasma corticosterone
levels were not statistically altered in either strain or by treatments
(Figure 8).
Discussion
Our study suggests a previously unrecognized but significant
role of the KCa3.1 channel in the control of behavior and central
monoaminergic transmission. We concluded this based on the
following findings: 1. Genetic deficiency of KCa3.1 significantly
increased locomotor activity without impairing neuromuscular
functions or body physics. Locomotor hyperactivity due to
KCa3.1-deficiency overcompensated for the locomotor hypoac-
tivity normally observed in KCa2.3T/T mice. 2. KCa3.1-deficien-
cy produced slightly impaired working/short term memory. 3.
Plasma catecholamine or corticosterone levels were not altered by
KCa3.1 deficiency. 4. In contrast, central monoaminergic
transmission was altered in several ways by KCa3.1 deficiency.
KCa3.12/2 mice exhibited significantly reduced turn-over rates of
5-HT in frontal cortex, striatum, and brain stem. Moreover,
KCa3.12/2 mice had reduced NA levels in brain stem and
cerebellum and exhibited increased NA turn-over rates in the
brain stem. 5. Administration of the selective KCa3.1/KCa2.X-
activator SKA-31 had opposite effects on behavior as it reduced
rearing, turning behavior, and home cage activity in a KCa3.1-
dependent fashion and at a high dosages produced strong sedation
in a KCa3.1/KCa2.3 independent manner, most likely related to
KCa2.2 activation. These data suggested that KCa3.1-deficient
mice show a type of attention-deficit hyperactivity disorder
(ADHD) phenotype, which is related to lower 5-HT turn-over
and lower NA levels in specifically the brain stem, but is not
related to alterations in sympathetic drive and chronic distress.
The efficacy of a selective KCa3.1/KCa2.X activator at reducing
locomotor activity proposed KCa3.1/KCa2.X-channels as novel
therapeutic targets for the treatment of human neurological
syndromes characterized by physical hyperactivity such as ADHD.
Considering possible mechanisms underlying the behavioral
alterations, our HPLC analysis of plasma and regional cerebral
monoamine levels revealed normal plasma catecholamine levels,
but several, brain-region specific changes in monoamine levels and
turnover rates in KCa3.12/2 mice, including reduced NA levels
and increased NA turn-over rate in the brain stem and frontal
cortex as well as reduced 5-HT turnover rates in the striatum and
brain stem. Particularly, the higher NA turn-over – pointing to
increased NA transmission – may be linked to the observed
hyperactivity in the KCa3.12/2 mice. However, whether these
changes are causally related to the observed hyperactivity, remains
unclear. A common finding in animal models of ADHD is
hyperdopaminergic function (increased DA turnover)(for review
see [42]), but this is apparently not the case in the KCa3.1-
deficient mice. However, because of cross-talk between the
monoaminergic systems, changes in NA and 5-HT transmission
can affect dopaminergic function and ADHD symptoms. Changes
in noradrenergic transmission and action on inhibitory alpha-2
autoreceptors can either enhance or ameliorate ADHD symptoms.
5-HT may play a role in hyperactivity, either directly through 5-
HT2 receptors or indirectly by modulating dopaminergic trans-
mission. Decreased activity of 5-HT has been reported in relation
to impulsivity in borderline personality, aggression and suicide,
while increased 5-HT activity and lower NA activity have been
associated with ADHD (for references see [43]). However, changes
in NA and/or 5-HT metabolism observed in clinical conditions or
animal models may not be directly – causally – linked to
hyperactivity, but rather reflect compensatory changes to coun-
teract hyperactivity or dysfunction of other monoaminergic
systems.
Recently, another KCa3.12/2 mouse has been reported to be
hyper-responsive to stress due to increased release of adrenocor-
ticotropic hormone (ACTH) and corticosterone, with no change in
basal corticosterone levels [29]. We likewise did not observe higher
plasma corticosterone or plasma levels of catecholamine suggesting
that the hyperactivity of our KCa3.1-deficient mice is not related
to higher chronic distress or overt sympathetic rush.
Unlike KCa3.1-deficient mice, KCa2.3T/T mice exhibited
significantly higher 5-HT levels in the frontal cortex and tended
to also exhibit higher 5-HIAA levels in striatum with no change in
5-HIAA and 5-HIAA/5-HT turn-over rates. These increases,
which are contrary to the decreases seen in KCa3.12/2 mice,
could represent a compensatory mechanism to mitigate the overt
hypoactivity in these animals. Higher 5-HT levels have been
reported for this strain earlier [28] and the present study also
showed that these alterations are presumably ‘‘developmental’’ as
2-week DOX-treatment and the resulting channel suppression had
no impact on the 5-HT levels in these mice. It is, however,
noteworthy that additional life-long KCa3.1-deficiency reduced
levels to those measured in wild type mice.
While KCa3.1-deficiency produced hyperactivity, the brain
penetrable KCa3.1/KCa2.X-activator SKA-31, with a 5-fold
higher selectivity for KCa3.1 over KCa2.X channels, had opposite
effects and produced hypoactivity and sedation in half of the
animals, which at the higher dose was largely KCa3.1- and
KCa2.3 independent as it occurred in KCa3.12/2 and
KCa2.3T/T with or without DOX treatment alike. This can be
explained by activation of KCa2.1 and KCa2.2 channels with a
more widespread expression in the murine brain [22] and is in line
with findings that higher doses of SKA-31 are anticonvulsant
presumably due to KCa2.2 activation [30] and acutely improve
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[44]. Nonetheless, at a lower dose of SKA-31 the reduction of
rearing and turning behavior depended on KCa3.1. Despite this
poor KCa3.1-dependence of the acute SKA-31-effects, SKA-31
had a ‘‘calming’’ effect on spontaneous home cage activity in the
wild-type, which was not observed in KCa3.12/2 mice, as
expected. The acute treatment with the high dose of SKA-31
significantly increased 5-HT in the striatum and brain stem of wild
type, but not in KCa3.12/2 mice, and significantly reduced 5-
HIAA/5-HT turn-over rates in brain stem and hypothalamus in a
KCa3.1-independent fashion, which suggested that these SKA-31-
effects are caused by activation of KCa2.X channels and involved
a reduced 5-HT release as reflected by the lower 5-HT turn-over
rate.
The mechanistic link between deficiency of KCa3.1 to the
behavioral alterations and the changes of cerebral monoamine
levels remains unclear. But we speculate that these alterations
could be related to the endothelial dysfunction (severely impaired
acetylcholine-induced vasodilation) and systolic hypertension
during locomotor activity in the KCa3.12/2 mice [11,31]. In this
regard KCa3.12/2 mice are similar to spontaneously hypertensive
rats (SHR), which are also hyperactive, show memory deficits and
alterations of monoaminergic neurotransmission, and thus neuro-
logical features similar to ADHD [42]. In contrast to our model,
however, 5-HT levels are increased in several brain regions in the
SHR model of ADHD. On the other hand, KCa3.12/2 (this
study) and SHR [45] appear to have a concordant higher central
NA activity.
In order to validate KCa3.1 deficient mice as an alternative
model of ADHD, the behavioral effects of chronic methylpheni-
date treatment should be investigated in further studies.
In conclusion, the present study revealed a novel mechanistic
link of the non-neuronal KCa3.1 channel to behavior, central
monoamine levels, and hyperactivity in mice. From the clinical
perspective, our pharmacological studies suggested that small
molecule activators of KCa3.1 may have beneficial ‘‘calming’’
effects in hyperactivity disorders, including ADHD.
Supporting Information
Figure S1 Similar performances of KCa3.12/2 and
C57Bl6J in the open field test. (A) Center/perimeter ratio,
(B) total distance travelled, (C) mean velocity, (D) entries into the
different zones. Data are given as means 6 SEM.
(TIF)
Figure S2 Original tracings of all open field test
experiments.
(TIF)
Figure S3 GABA levels in the different brain areas from
KCa3.12/2 (2/2) and KCa3.1+/+ (+/+). Data are given as
means 6 SEM.
(TIF)
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